title: [The influence of water soluble antioxidant agent (mexidol) on optic nerve and blood flow velocity in ocular and orbital arteries in patients with primary open-angle glaucoma].
abstract: The prospective single-blind placebo-controlled randomized trial is devoted to influence of mexidol (2-ethil-6-methil-3-hydroxipiridine succinate) on dynamics of optic nerve electrophysiologic profile and velocity indices of blood flow in ocular and orbital arteries in correlation with changes of retinal photosensitivity, visual acuity and visual field size during course of intravenous mexidol infusions and standard treatment of primary open-angle glaucoma. 2 weeks of intravenous infusions of 300 mg mexidol daily was found to cause depression of optic nerve electrical sensitivity threshold and widening of total visual field (16 mm2 test stimulus) after 14 days of treatment. These effects were not associated with changes of blood flow velocity in ocular and orbital arteries, were transient and came to initial indices 3 months after the end of treatment. Delayed vasotropic effect of mexidol manifested in increase of blood flow velocity in central retinal artery in 90 days after the end of infusions.
authors.forename: I A
authors.initials: IA
authors.lastname: Volchegorskiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Tur
authors.forename: O V
authors.initials: OV
authors.lastname: Soliannikova
authors.forename: V S
authors.initials: VS
authors.lastname: Rykun
authors.forename: E V
authors.initials: EV
authors.lastname: Berdnikova
authors.forename: M S
authors.initials: MS
authors.lastname: Sumina
authors.forename: V N
authors.initials: VN
authors.lastname: Dmitrienko
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000493:pharmacokinetics; D001158:Arteries / Q000000981:diagnostic imaging; D001783:Blood Flow Velocity / Q000187:drug effects*; D005123:Eye / Q000098:blood supply / Q000503:physiopathology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009900:Optic Nerve / Q000503:physiopathology; D010847:Picolines / Q000008:administration & dosage / Q000493:pharmacokinetics; D016037:Single-Blind Method; D016896:Treatment Outcome; D018615:Ultrasonography, Doppler, Color; D014785:Vision, Ocular / Q000187:drug effects*; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
chemical_list: D000975:Antioxidants; D010847:Picolines; C070020:emoxypine succinate